GlassScriptPhysician profile
Travis Anderson
NPI 1083177513
$1,979.42
in general payments reported to CMS, 2019-2025
14 companies · $790 in 2025
The $790 reported for 2025 was more than what 85% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $181 · 2024: $1,008 · 2025: $790.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,966 · Education: $13.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,965.98 |
| Education | $13.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $1,168.25 | 2024-2025 | Impella |
| Kestra Medical Technology Services, INC. | $152.90 | 2025 | Assure Wcd |
| Pfizer INC. | $136.40 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $124.33 | 2023-2025 | Camzyos, Eliquis |
| Boston Scientific Corporation | $106.64 | 2025 | Watchman Flx |
| Amgen INC. | $80.55 | 2023 | Repatha |
| Abbott Laboratories | $54.30 | 2025 | Aveir, Thoratec Heartmate 3 Lvas Implant Kit |
| Novartis Pharmaceuticals Corporation | $32.53 | 2024 | |
| Cvrx, INC. | $29.50 | 2025 | Barostim Neo System |
| Actelion Pharmaceuticals US, INC. | $29.32 | 2025 | Uptravi |
| Daiichi Sankyo INC. | $21.96 | 2024 | Injectafer |
| Janssen Pharmaceuticals, INC | $14.99 | 2024 | Xarelto |
| Olympus America INC. | $13.99 | 2024 | Visera Elite II Video System Center |
| Merck Sharp & Dohme LLC | $13.76 | 2024 | Verquvo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Travis Anderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.